ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1673

Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study

Anirudh Bandu1, Michal Cidon2 and Michael Weisman3, 1CHLA, Los Angeles, NJ, 2Children's Hospital of Los Angeles, Los Angeles, CA, 3Cedars-Sinai Medical Center, LOS ANGELES, CA

Meeting: ACR Convergence 2025

Keywords: Ankylosing spondylitis (AS), Pediatric rheumatology, Reactive arthritis, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)

Session Type: Abstract Session

Session Time: 2:15PM-2:30PM

Background/Purpose: Transient synovitis (TS) of the hip is considered a common, self-limited condition in the pediatric population. However, recurrences can occur; these may signal an early manifestation of enthesitis-related arthritis (ERA) or Juvenile Spondylarthritis (SpA). We conducted a retrospective chart review study that identified the initial visit of all coded transient synovitis cases from 2002 to 2022 and attempted to contact these patients by telephone. The study goal was to determine, through direct interview, whether these patients had recurrent disease and subsequent clinical features indicative of early juvenile spondylarthritis (SpA) or enthesitis-related arthritis (ERA).

Methods: Data collected from the initial chart review included demographics and details from the initial ED visit. A follow-up by telephone interview obtained data on the recurrence of transient synovitis, chronic back pain (lasting > 6 weeks), joint pain, and physician diagnoses such as Enthesitis Related Arthritis, Juvenile SpA, or related conditions after obtaining consent.

Results: A Total of 184 charts were analyzed after review to determine the accurate diagnosis of transient synovitis; 74 patients (40%) were successfully contacted. The demographics and clinical features of the 74 contacted were no different from those of the 110 who were unable to be contacted. [Refer to Figure 1] One third of the contacted patients reported recurrent transient synovitis; these subjects exhibited significantly higher rates of musculoskeletal pain compared to those with non-recurrent transient synovitis. Chronic back pain was reported in 41.7% of the recurrent transient synovitis group vs. 0% of the non-recurrent group (p < 0.001). Chronic peripheral pain was present in 66.7% in the recurrent group vs. 8.0% in the non-recurrent group (OR 21.6, 95% CI: 5.3–113.0, p < 0.001). Combined chronic peripheral and back pain was present in 75.0% in the recurrent group vs. 8.0% in the non-recurrent group (OR 31.8, 95% CI: 7.5–176.9, p < 0.01). Pain localized to hips, knees, and ankles was significantly more common in recurrent cases (p < 0.005). Absence of pain was strongly associated with the non-recurrent group (92.0% vs. 33.3%, p < 0.001). [Refer to Figure 2]

Conclusion: Recurrent transient synovitis may be an early indicator of Juvenile SpA or Enthesitis Related Arthritis. In our retrospective cohort, one-third of transient synovitis cases reported recurrence of transient synovitis. Of those who reported recurrences, a substantial number of participants also indicated additional symptoms that are concerning for a developing enthesitis related arthritis or Juvenile SpA such as chronic back pain and lower extremity pain. Recurrent transient synovitis may signify an important precursor to Juvenile SpA or enthesitis related arthritis and potentially be considered a risk factor. These findings support the need for ongoing follow-up with pediatric rheumatology. A future prospective study would be necessary to establish a diagnosis of Enthesitis Related Arthritis or Juvenile SpA in individuals who experienced recurrent transient synovitis.

Supporting image 1Demographic comparison of Contacted vs Unable to Contacted

Supporting image 2No TS Recurrence versus TS Recurrence


Disclosures: A. Bandu: None; M. Cidon: None; M. Weisman: Spyre Therapeutics, 1, 2.

To cite this abstract in AMA style:

Bandu A, Cidon M, Weisman M. Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/is-transient-synovitis-of-the-hip-preclinical-juvenile-spa-a-follow-up-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-transient-synovitis-of-the-hip-preclinical-juvenile-spa-a-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology